Abstract
Lars Masanneck, Elaine Trautmann, Judith von Pavel, Ramona Hagler, Marius Vach, Patricia Kirschner, Jan Voth, Melanie Schuette, Pascal Benkert, Jens Kühle, Jörn Kaufmann, Marie Deffner, Nicholas Schwab, Steffen Pfeuffer, Sven Guenther Meuth, Marc Pawlitzki
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
10.1016/s1474-4422(22)00143-0 · 2022
A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
10.1177/13524585211003020 · 2021
Pharmacokinetics and pharmacodynamics of natalizumab 6-Week dosing vs continued 4-Week dosing for relapsing-remitting multiple sclerosis
10.1212/nxi.0000000000200321 · 2024
Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis
10.1007/s13760-024-02480-6 · 2024
Extended interval dosing of natalizumab in multiple sclerosis
10.1136/jnnp-2015-312940 · 2016
Wearing-off symptoms during standard and extended natalizumab dosing intervals: experiences from the COVID-19 pandemic
10.1016/j.jns.2021.117622 · 2021
The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms
10.1212/wnl.0000000000008357 · 2019
End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?
10.1016/j.msard.2020.102020 · 2020
Natalizumab wearing-off effect: the hunt for the elusive pharmacodynamic biomarker
10.1212/nxi.0000000000000706 · 2020
Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy
10.1212/nxi.0000000000000678 · 2020
Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: a prospective 1-year follow-up study
10.1016/j.jns.2020.116880 · 2020
Improvement of fatigue, depression, and processing speed two weeks post natalizumab infusion in multiple sclerosis: no difference between standard and extended interval dosing schedules
10.1016/j.msard.2024.106146 · 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
10.1177/13524585241293940 · 2024
Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
10.1212/nxi.0000000000000271 · 2016
Effect of natalizumab on sNfL and sGFAP levels in multiple sclerosis patients
10.3390/ijms252313153 · 2024
Identifying the start of multiple sclerosis injury: a serial DTI study
10.1111/jon.12082 · 2014
Measuring brain tissue integrity during 4 years using diffusion tensor imaging
10.3174/ajnr.a4946 · 2017
[digital medicine in neurological research-between hype and evidence]
10.1007/s00115-023-01581-6 · 2024
Evidence from clinicalTrials.gov on the growth of digital health technologies in neurology trials
10.1038/s41746-023-00767-1 · 2023
Digital activity markers in chronic inflammatory demyelinating polyneuropathy
10.1002/acn3.70137 · 2025
Continuous daily assessment of multiple sclerosis disability using remote step count monitoring
10.1007/s00415-016-8334-6 · 2017
Modeling multiple sclerosis using Mobile and wearable sensor data
10.1038/s41746-024-01025-8 · 2024
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
10.1016/s1474-4422(17)30470-2 · 2018
The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment
10.1177/135245859900500409 · 1999
MRtrix3: a fast, flexible and open software framework for medical image processing and visualisation
10.1016/j.neuroimage.2019.116137 · 2019
Denoising of diffusion MRI using random matrix theory
10.1016/j.neuroimage.2016.08.016 · 2016
Gibbs-ringing artifact removal based on local subvoxel-shifts
10.1002/mrm.26054 · 2016
An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging
10.1016/j.neuroimage.2015.10.019 · 2016
How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging
10.1016/s1053-8119(03)00336-7 · 2003
Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data
10.1016/j.neuroimage.2006.02.024 · 2006
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
10.1016/s1474-4422(22)00009-6 · 2022
Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under b-cell depleting treatment in multiple sclerosis
10.1002/ana.27096 · 2025
Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay
10.1016/j.cca.2025.120447 · 2025
Annual 12-Week dosing gap of natalizumab: clinical efficacy, blood biomarkers, and CSF cell composition
10.1002/acn3.70207 · 2026
The physical activity guidelines for Americans
10.1001/jama.2018.14854 · 2018
2024 adult compendium of physical activities: a third update of the energy costs of human activities
10.1016/j.jshs.2023.10.010 · 2024
Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis
10.1136/jnnp-2024-335673 · 2025
Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathy
2024
A systematic review of microstructural abnormalities in multiple sclerosis detected with NODDI and DTI models of diffusion-weighted magnetic resonance imaging
10.1016/j.mri.2023.09.010 · 2023
White matter diffusion changes during the first year of natalizumab treatment in relapsing-remitting multiple sclerosis
10.3174/ajnr.a4690 · 2016
Assessment of hypertension control among adults participating in a Mobile technology blood pressure self-Management program
10.1001/jamanetworkopen.2021.27008 · doi-reference
Long-term adherence to a wearable for continuous behavioural activity measuring in the SafeHeart implantable cardioverter defibrillator population
10.1093/ehjdh/ztae055 · doi-reference
Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity
10.1016/j.msard.2023.105104 · doi-reference
White matter diffusion changes during the first year of natalizumab treatment in relapsing-remitting multiple sclerosis
10.3174/ajnr.a4690 · doi-reference
A systematic review of microstructural abnormalities in multiple sclerosis detected with NODDI and DTI models of diffusion-weighted magnetic resonance imaging
10.1016/j.mri.2023.09.010 · doi-reference
Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis
10.1136/jnnp-2024-335673 · doi-reference
2024 adult compendium of physical activities: a third update of the energy costs of human activities
10.1016/j.jshs.2023.10.010 · doi-reference
The physical activity guidelines for Americans
10.1001/jama.2018.14854 · doi-reference
Annual 12-Week dosing gap of natalizumab: clinical efficacy, blood biomarkers, and CSF cell composition
10.1002/acn3.70207 · doi-reference
Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay
10.1016/j.cca.2025.120447 · doi-reference
Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under b-cell depleting treatment in multiple sclerosis
10.1002/ana.27096 · doi-reference
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
10.1016/s1474-4422(22)00009-6 · doi-reference
Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data
10.1016/j.neuroimage.2006.02.024 · doi-reference
How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging
10.1016/s1053-8119(03)00336-7 · doi-reference
An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging
10.1016/j.neuroimage.2015.10.019 · doi-reference
Gibbs-ringing artifact removal based on local subvoxel-shifts
10.1002/mrm.26054 · doi-reference
Denoising of diffusion MRI using random matrix theory
10.1016/j.neuroimage.2016.08.016 · doi-reference
MRtrix3: a fast, flexible and open software framework for medical image processing and visualisation
10.1016/j.neuroimage.2019.116137 · doi-reference
The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment
10.1177/135245859900500409 · doi-reference
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
10.1016/s1474-4422(17)30470-2 · doi-reference
Modeling multiple sclerosis using Mobile and wearable sensor data
10.1038/s41746-024-01025-8 · doi-reference
Continuous daily assessment of multiple sclerosis disability using remote step count monitoring
10.1007/s00415-016-8334-6 · doi-reference
Digital activity markers in chronic inflammatory demyelinating polyneuropathy
10.1002/acn3.70137 · doi-reference
Evidence from clinicalTrials.gov on the growth of digital health technologies in neurology trials
10.1038/s41746-023-00767-1 · doi-reference
[digital medicine in neurological research-between hype and evidence]
10.1007/s00115-023-01581-6 · doi-reference
Measuring brain tissue integrity during 4 years using diffusion tensor imaging
10.3174/ajnr.a4946 · doi-reference
Identifying the start of multiple sclerosis injury: a serial DTI study
10.1111/jon.12082 · doi-reference
Effect of natalizumab on sNfL and sGFAP levels in multiple sclerosis patients
10.3390/ijms252313153 · doi-reference
Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
10.1212/nxi.0000000000000271 · doi-reference
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
10.1177/13524585241293940 · doi-reference
Improvement of fatigue, depression, and processing speed two weeks post natalizumab infusion in multiple sclerosis: no difference between standard and extended interval dosing schedules
10.1016/j.msard.2024.106146 · doi-reference
Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: a prospective 1-year follow-up study
10.1016/j.jns.2020.116880 · doi-reference
Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy
10.1212/nxi.0000000000000678 · doi-reference
Natalizumab wearing-off effect: the hunt for the elusive pharmacodynamic biomarker
10.1212/nxi.0000000000000706 · doi-reference
End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?
10.1016/j.msard.2020.102020 · doi-reference
The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms
10.1212/wnl.0000000000008357 · doi-reference
Wearing-off symptoms during standard and extended natalizumab dosing intervals: experiences from the COVID-19 pandemic
10.1016/j.jns.2021.117622 · doi-reference
Extended interval dosing of natalizumab in multiple sclerosis
10.1136/jnnp-2015-312940 · doi-reference
Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis
10.1007/s13760-024-02480-6 · doi-reference
Pharmacokinetics and pharmacodynamics of natalizumab 6-Week dosing vs continued 4-Week dosing for relapsing-remitting multiple sclerosis
10.1212/nxi.0000000000200321 · doi-reference